These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10997418)

  • 21. Determination of HIV-1 circular DNA as a surrogate marker for residual virus replication in patients with undetectable virus loads.
    Hauber I; Harrer T; Löw P; Schmitt M; Schwingel E; Hauber J
    AIDS; 2000 Nov; 14(16):2619-21. PubMed ID: 11101080
    [No Abstract]   [Full Text] [Related]  

  • 22. Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy.
    Walmsley SL; Kelly DV; Tseng AL; Humar A; Harrigan PR
    AIDS; 2001 Aug; 15(12):1581-4. PubMed ID: 11504994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lamivudine for chronic hepatitis B and HIV co-infection.
    Carton JA; Maradona JA; Asensi V; Rodríguez M; Martínez A
    AIDS; 1999 May; 13(8):1002-3. PubMed ID: 10371189
    [No Abstract]   [Full Text] [Related]  

  • 24. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.
    Hecht FM; Grant RM; Petropoulos CJ; Dillon B; Chesney MA; Tian H; Hellmann NS; Bandrapalli NI; Digilio L; Branson B; Kahn JO
    N Engl J Med; 1998 Jul; 339(5):307-11. PubMed ID: 9682043
    [No Abstract]   [Full Text] [Related]  

  • 25. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.
    Martin C; Sönnerborg A; Svensson JO; Ståhle L
    AIDS; 1999 Jul; 13(10):1227-32. PubMed ID: 10416527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using non-nucleoside reverse transcriptase inhibitors in treating HIV disease: where are the therapeutic niches?
    Idemyor V
    J Natl Med Assoc; 2000 Feb; 92(2):99-101. PubMed ID: 10800301
    [No Abstract]   [Full Text] [Related]  

  • 27. Early intensification with abacavir in subjects at high risk for incomplete viral suppression.
    Bartlett JA; Tebas P; Bassett R; Huang W; Kuritzkes D; Reisler R; Loyack N; Robison K;
    Antivir Ther; 2003 Aug; 8(4):361-3. PubMed ID: 14518706
    [No Abstract]   [Full Text] [Related]  

  • 28. An introduction to HIV drug resistance testing.
    Bean P
    Am Clin Lab; 2000 May; 19(4):10-1. PubMed ID: 10947312
    [No Abstract]   [Full Text] [Related]  

  • 29. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission of HIV myelopathy after highly active antiretroviral therapy.
    Staudinger R; Henry K
    Neurology; 2000 Jan; 54(1):267-8. PubMed ID: 10636172
    [No Abstract]   [Full Text] [Related]  

  • 31. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term HIV-1 suppression in the Brazilian public health system.
    de Sa-Filho DJ; de Arruda Souza T; Golegã AA; Diaz RS; Caseiro MM
    AIDS Patient Care STDS; 2009 May; 23(5):313-4. PubMed ID: 19327023
    [No Abstract]   [Full Text] [Related]  

  • 33. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy.
    Fischer T; Schwörer H; Vente C; Reich K; Ramadori G
    AIDS; 1999 Apr; 13(5):628-9. PubMed ID: 10203394
    [No Abstract]   [Full Text] [Related]  

  • 35. Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimens.
    Ripamonti D; Arici C; Maggiolo F; Finazzi MG; Suter F
    AIDS; 2002 Jan; 16(1):130-1. PubMed ID: 11741174
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV drug resistance.
    Clavel F; Hance AJ
    N Engl J Med; 2004 Mar; 350(10):1023-35. PubMed ID: 14999114
    [No Abstract]   [Full Text] [Related]  

  • 37. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.
    Cunningham PH; Smith DG; Satchell C; Cooper DA; Brew B
    AIDS; 2000 Sep; 14(13):1949-54. PubMed ID: 10997399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of significant viral load alterations of hepatitis B virus and hepatitis C virus during treatment with IL-2 and highly active antiretroviral therapy.
    Hengge UR; Roggendorf M; Goos M
    AIDS; 2000 Nov; 14(16):2617-9. PubMed ID: 11101079
    [No Abstract]   [Full Text] [Related]  

  • 39. Higher antiviral activity of antiretroviral regimens including protease inhibitors.
    de Mendoza C; Soriano V; Rodríguez-Rosado R; González-Lahoz J
    AIDS; 1999 May; 13(8):998-9. PubMed ID: 10371186
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
    Karlström O; Ståhle L; Perrin L; Tegude H; Sönnerborg A
    Scand J Infect Dis; 2006; 38(5):371-4. PubMed ID: 16709540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.